MedPath

EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery

Not yet recruiting
Conditions
Colorectal Cancer
Registration Number
NCT06690606
Lead Sponsor
Shanghai University of Traditional Chinese Medicine
Brief Summary

The goal of this observational study is to develop a predictive model for overall survival in patients under the age of 50 who have undergone surgery for early-onset colorectal cancer (EOCRC). The main question it aims to answer is:

Can machine learning models accurately predict the long-term survival of EOCRC patients after surgical treatment?

Participants who have already undergone surgery for EOCRC as part of their regular medical care will have their clinical data analyzed, with survival outcomes tracked through follow-up assessments. An online survival calculator will also be developed to aid clinicians and patients in predicting personalized survival outcomes.

Detailed Description

To avoid duplicating information that will be entered or uploaded elsewhere in the record, here is a concise summary of the key components of the study:

* Study Title\*\*: \*EOCRCPred: An AI Model to Predict Survival in Early-onset Colorectal Cancer Patients After Surgery\*

* Introduction\*\*:

This study addresses the increasing incidence and mortality of early-onset colorectal cancer (EOCRC) in patients under 50. EOCRC exhibits distinct clinical and pathological features compared to late-onset CRC, including higher recurrence rates and advanced disease stages at diagnosis. Current predictive models for postoperative outcomes in EOCRC are limited, highlighting the need for specialized tools to guide treatment decisions.

* Objectives\*\*:

1. Develop AI models for predicting overall survival (OS) in postoperative M0 EOCRC patients.

2. Propose a new survival risk stratification system.

3. Deploy an online survival calculator to assist clinical decision-making.

* Methods\*\*:

* \*\*Data Source\*\*: SEER database (2010-2019) for training/testing; two Chinese hospitals for external validation (2014-2024).

* \*\*Inclusion Criteria\*\*: Pathologically confirmed primary EOCRC, radical surgery (stage I-III), and complete follow-up.

* \*\*Models\*\*: Six predictive models, including CoxPH, RSF, S-SVM, XGBSE, GBSA, and DeepSurv.

* \*\*Evaluation Metrics\*\*: Discrimination (C-index, time-dependent AUC), calibration (Brier score, calibration curves), and clinical utility (Decision Curve Analysis).

* Statistical Analysis\*\*:

Comparisons were made using t-tests, Mann-Whitney U tests, and chi-square tests, with P \< 0.05 indicating significance.

\*\*Risk Stratification\*\*: Risk groups were classified based on RSF-derived scores (low, intermediate, high), and survival differences were assessed via Kaplan-Meier curves and log-rank tests.

This streamlined summary covers the primary goals, methodology, and analysis without repeating specifics that will be detailed in other sections of the record.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Primary EOCRC confirmed by pathological histological examination (ICD-10 codes: C18.0, C18.2-18.9, C19.9, C20.9)
  • Radical surgery performed (Specific Surgery Codes 30-70, including partial/subtotal colectomy, hemicolectomy, right/left colectomy, and total colectomy, as well as partial or total removal of other organs and regional lymph nodes)
  • Stage I-III disease according to the 7th AJCC-TNM system
Exclusion Criteria
  • Patients with multiple primary cancers or other malignancies
  • Survival time of less than 1 month, or absence of postoperative follow-up information
  • Incomplete critical clinical feature information

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of Clinical Characteristics and Survival Status of Subjects Using the CRF Scale2024.11

Age, Gender, Race, Primary Site, Tumor Diameter, Differentiation Degree, Histology, TNM Stage, CEA, Surgery Type, Number of Resected Lymph Nodes, Tumor Deposits, Neural Invasion, Radiation Sequence, Chemotherapy Sequence, Systemic Therapy Sequence, Marital Status, Household Income, Survival Status, Postoperative Survival Time.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Putuo Hospital, Shanghai University of Traditional Chinese Medicine

🇨🇳

Shanghai, China

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath